Blue Owl Capital Holdings’s Palvella Therapeutics PVLA Stock Holding History

Blue Owl Capital Holdings’s Portfolio PVLA Stock Details PVLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$5.54M	Buy	36,259 +5,000	+16%	+$607K	0.83%	21
2026 Q1	$3.9M	Sell	31,259 -9,000	-22%	-$939K	1.05%	25
2025 Q4	$4.21M	Sell	40,259 -55,000	-58%	-$4.69M	1.3%	23
2025 Q3	$5.97M	Sell	95,259 -30,000	-24%	-$1.34M	1.85%	19
2025 Q2	$2.82M	Sell	125,259 -15,000	-11%	-$352K	0.91%	26
2025 Q1	$3.93M	Sell	140,259 -109,803	-44%	-$2.12M	1.27%	22
2024 Q4	$3M	Buy	+250,062	New	+$3.93M	0.69%	28

Other funds holding PVLA

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

FCM

Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Blue Owl Capital Holdings's PVLA Position: Q2 2026 in Review

Blue Owl Capital Holdings increased its Palvella Therapeutics (PVLA) stake by 16% in Q2 2026, buying an estimated $607K and bringing the position to 36,259 shares worth $5.54M. The position accounts for 0.83% of the portfolio, ranked #21.

Blue Owl Capital Holdings first reported a position in PVLA in Q4 2024 and has held it in 7 quarters since. The position peaked at $5.97M in Q3 2025. 196 funds tracked by Wall St. Rank hold PVLA as of Q2 2026.

Blue Owl Capital Holdings held 36,259 shares of Palvella Therapeutics worth $5.54M as of Q2 2026.
Blue Owl Capital Holdings bought 5,000 Palvella Therapeutics shares in Q2 2026, an estimated $607K.
Palvella Therapeutics made up 0.83% of Blue Owl Capital Holdings's portfolio in Q2 2026, its #21 holding.
Blue Owl Capital Holdings first reported a position in Palvella Therapeutics in Q4 2024 and has held it in 7 quarters since.
Blue Owl Capital Holdings's Palvella Therapeutics position peaked at $5.97M in Q3 2025.
196 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q2 2026.

Based on Blue Owl Capital Holdings's 13F filing for Q2 2026, filed 11 Aug 2026.